适应肿瘤个体化治疗需求促进我国分子诊断事业健康发展  

Adapting the demands of tumor individualized therapy and promoting the development of molecular diagnostic career in China

作　　者：石远凯[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院肿瘤研究所内科、抗肿瘤分子靶向药物临床研究北京市重点实验室,100021

出　　处：《中华检验医学杂志》2012年第11期961-962,共2页Chinese Journal of Laboratory Medicine

基　　金：基金项目：国家高技术研究发展计划（863计划）资助项目（2011AA02A110）;国家重大新药创制科技重大专项资助项目（2012ZX09303012）;卫生部卫生公益性行业科研专项资助项目（200902002-1）

摘　　要：目前，恶性肿瘤治疗已进入以分子靶向治疗为代表的个体化治疗时代。靶向治疗显著延长了患者的生存期，减轻了传统化疗相关的毒副反应，改善了生活质量。准确的个体化靶向治疗的前提是针对分子靶点的精确诊断，因此，对我国相关实验室技术人员的培训和检测肿瘤基因技术的规范化统一管理已迫在眉睫。分子靶点诊断最理想的标本来源是患者肿瘤组织（白血病等血液肿瘤例外），但是相当一部分患者由于受各种原因的限制，无法得到满意的肿瘤组织，所以探索其他替代标本来源，如外周血和恶性体腔积液的临床意义备受关注。此外，肿瘤临床分子流行病学研究同样是肿瘤个体化分子靶向治疗的重要研究领域之一。Recently,the therapy for malignant tumor has entered the era of individualized molecular targeted therapy. Targeted therapy could significantly improve survival, reduce chemotherapy related toxicity, improve quality of life. Precise individualized therapy is based on accurate diagnosis of molecular targets. Therefore, it is very important and urgent for China to establish normative training system for laboratory technicians and uniform management of testing methods. The most ideal samples for testing are primary tumor tissues （except malignant hematologic diseases）, but the tumor samples in a large amount of patients could not be obtained for some reasons. Therefore, exploring other originated samples such as blood and malignant body cavity effusion has attracted considerable attention. Molecular epidemiology study of gene mutations in tumor patients is also one of the most important areas for individualized targeted therapy.

关 键 词：肿瘤 肿瘤标志物 生物学 诊断 

分 类 号：R544.1[医药卫生—心血管疾病]